CG Oncology's Successful IPO Sets Positive Tone for Biotech Public Offerings
TL;DR Summary
CG Oncology's $380 million IPO debut could serve as a barometer for the future of public offerings in 2023, as the biotech industry sees a potential increase in IPO activity following a significant decrease in the past two years. Industry insiders caution against drawing conclusions based on one company, but with at least five other biotechs poised to follow suit, more data points will soon be available.
- Is CG Oncology's IPO a benchmark for a better year in public offerings? Endpoints News
- Bladder cancer biotech CG Oncology raises $380 million in IPO Axios
- CG Oncology, Inc. Rings the Opening Bell Nasdaq
- CG Oncology Shares Rise 63% in Debut MarketWatch
- In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M FierceBiotech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
51%
136 → 67 words
Want the full story? Read the original article
Read on Endpoints News